Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1605)	3/27/2001 1:19:08 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2344

Biomira Inc. Gets U.S. Patent For Cancer Vaccine Program Dow Jones Newswires EDMONTON -- Biomira Inc.'s (BIOM) Biomira USA unit was issued a patent from the U.S. Patent and Trademark Office for composition of matter used in Biomira's cancer-vaccine program. In a press release, the company said the patent, number 6,207,170, is entitled "Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes (MPL)". It said the patent describes a new composition of matter and a cost-effective method for treating patients with an autologous vaccine. The vaccine is a membrane proteoliposome structure comprising one or more entities from the group of cytokines, costimulatory molecules, immune stimulators or adjuvants Biomira said it received clearance from the Food and Drug Administration to proceed with a Phase Ib trial in patients with B-Cell lymphoma utilizing this vaccine approach. This trial will be conducted at the U.S. National Cancer Institute, as well as two cancer centers in New Jersey. Biomira is a biotechnology company. Company Web Site: biomira.com